BRIEF—Astellas to build new Prograf manufacturing plant

Drugmaker Astellas is to build a new manufacturing facility for the active pharmaceutical ingredient (API) of Prograf (tacrolimus hydrate) at the group’s Toyama Technology Center in Japan.

The Japanese company wants to enhance its production capacity, enabling a stable supply of high-quality products in the future, taking into account the expected steady demand for Prograf, which has already greatly contributed to medical transplantation globally as a first-line immunosuppressant for organ transplantation.

Building of the facility is expected to be completed by August 2021, with the cost anticipated to come in at around $91 million.